At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 180 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Centre Study To Investigate The Safety And Efficacy Of CP-690,550 For Maintenance Therapy In Subjects With Moderate To Severe Crohn's Disease
In Brief
A Phase 2 clinical trial evaluating Placebo and CP-690,550 for Crohn's Disease. Completed, enrolled 180 participants across 91 sites in 17 countries.
Detailed Summary
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or clinical remission (CDAI\<150) at Week 8.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCrohn's Disease
CountriesAustralia, Austria, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Japan, Netherlands, South Africa, South Korea, Spain, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJul 2011
Enrollment StartMar 2012
Primary CompletionJul 2015
TodayJul 2026
First PostedJul 13, 2011
Enrollment StartMar 1, 2012
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 15.0 years ago
Interventions
Placebodrug
oral tablets twice daily
CP-690,550drug
oral tablets twice daily
CP-690,550drug
oral tablets twice daily